Elsevier established a free COVID-19 resource center in January 2020, offering English and Mandarin information on the virus. The center is hosted on Elsevier Connect, a public news and information website. Elsevier grants permission to make all COVID-19-related research freely available in PubMed Central and other public repositories for unrestricted research use. The article discusses the role of neutrophil extracellular traps (NETs) in immunothrombosis in COVID-19 acute respiratory distress syndrome (ARDS). NETs, formed by neutrophils, can trigger immunothrombosis, contributing to thrombotic events in COVID-19 patients. The study found that plasma levels of MPO-DNA complexes, a marker of NETs, increased in COVID-19 patients, correlating with disease severity and mortality. The study also found that COVID-19 patients had higher levels of platelet factor 4 (PF4) and RANTES, which are known to trigger NET formation. Neonatal NET-inhibitory factor (nNIF), a peptide found in human umbilical cord blood, was shown to inhibit NET formation induced by COVID-19 plasma. This suggests that nNIF could be a potential therapeutic intervention for COVID-19. The study highlights the role of NETs in the pathogenesis of COVID-19, contributing to thrombo-inflammatory cascades and hypercoagulability. The findings suggest that targeting NETs may be a promising therapeutic approach for COVID-19. The study also emphasizes the importance of understanding the mechanisms of NET formation and its interaction with platelets in the context of COVID-19.Elsevier established a free COVID-19 resource center in January 2020, offering English and Mandarin information on the virus. The center is hosted on Elsevier Connect, a public news and information website. Elsevier grants permission to make all COVID-19-related research freely available in PubMed Central and other public repositories for unrestricted research use. The article discusses the role of neutrophil extracellular traps (NETs) in immunothrombosis in COVID-19 acute respiratory distress syndrome (ARDS). NETs, formed by neutrophils, can trigger immunothrombosis, contributing to thrombotic events in COVID-19 patients. The study found that plasma levels of MPO-DNA complexes, a marker of NETs, increased in COVID-19 patients, correlating with disease severity and mortality. The study also found that COVID-19 patients had higher levels of platelet factor 4 (PF4) and RANTES, which are known to trigger NET formation. Neonatal NET-inhibitory factor (nNIF), a peptide found in human umbilical cord blood, was shown to inhibit NET formation induced by COVID-19 plasma. This suggests that nNIF could be a potential therapeutic intervention for COVID-19. The study highlights the role of NETs in the pathogenesis of COVID-19, contributing to thrombo-inflammatory cascades and hypercoagulability. The findings suggest that targeting NETs may be a promising therapeutic approach for COVID-19. The study also emphasizes the importance of understanding the mechanisms of NET formation and its interaction with platelets in the context of COVID-19.